SCHEMBL29655172

SCHEMBL29655172

Nc1cc(-c2cc(Cc3n[nH]c(=O)c4ccccc34)ccc2F)cc(Cl)c1N

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.55
ENPP1 P22413 1/20 0.51
PARP1 P09874 10/20 0.50
HTT P42858 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
HDAC1 Q13547 1/20 0.48
PARP2 Q9UGN5 2/20 0.47
TUBB4A P04350 1/20 0.47
TUBB P07437 1/20 0.47
TUBA3C P0DPH7 1/20 0.47
TPI1 P60174 1/20 0.47
TUBA1B P68363 1/20 0.47
TUBA4A P68366 1/20 0.47
TUBB4B P68371 1/20 0.47
TUBB3 Q13509 1/20 0.47
TUBB2A Q13885 1/20 0.47
TUBB8 Q3ZCM7 1/20 0.47
TUBA3E Q6PEY2 1/20 0.47
TUBA1A Q71U36 1/20 0.47
TUBA1C Q9BQE3 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21528284 1.00 LMNA (0.55) LMNAENPP1PARP1HTTNPSR1
SCHEMBL30089698 0.91 ENPP1 (0.53) LMNAENPP1PARP1HDAC1PARP2
SCHEMBL19748667 0.91 ENPP1 (0.53) LMNAENPP1PARP1HDAC1PARP2
SCHEMBL19747598 0.87 LMNA (0.49) LMNAENPP1PARP1HTTNPSR1
SCHEMBL29655020 0.85 PARP1 (0.54) LMNAENPP1PARP1HDAC1PARP2
SCHEMBL19748615 0.85 PARP1 (0.54) LMNAENPP1PARP1HDAC1PARP2
SCHEMBL19748213 0.85 LMNA (0.58) LMNAENPP1PARP1HTTNPSR1
SCHEMBL4572859 0.83 ENPP1 (0.56) LMNAENPP1PARP1PARP2TUBB4A
SCHEMBL19748904 0.83 PARP1 (0.53) LMNAENPP1PARP1HDAC1PARP2
SCHEMBL29655103 0.83 PARP1 (0.53) LMNAENPP1PARP1HDAC1PARP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109843874-B Phthalazine derivatives useful as inhibitors of PARP1, PARP2 and/or tubulin for the treatment of cancer 加利福尼亚大学董事会 2022-05-27 CN disclosed